We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
+1.73%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$124M
AUM Growth
-$34.4M
Cap. Flow
-$23.6M
Cap. Flow %
-19.02%
Top 10 Hldgs %
58.94%
Holding
58
New
20
Increased
14
Reduced
17
Closed
6

Top Buys

1
INO icon
Inovio Pharmaceuticals
INO
+$4.65M
2
TELA icon
TELA Bio
TELA
+$3.5M
3
ENTA icon
Enanta Pharmaceuticals
ENTA
+$3.18M
4
IKT icon
Inhibikase Therapeutics
IKT
+$2.82M
5
OPTN
OptiNose
OPTN
+$1.84M

Top Sells

1
ADMA icon
ADMA Biologics
ADMA
+$11.8M
2
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$7.77M
3
RPRX icon
Royalty Pharma
RPRX
+$6M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$5.3M
5
RIGL icon
Rigel Pharmaceuticals
RIGL
+$5M

Sector Composition

1 Healthcare 99.91%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADMA icon
1
ADMA Biologics
ADMA
$2.02B
$21.3M 17.18%
1,241,032
-628,968
-34% -$11.8M
EOLS icon
2
Evolus
EOLS
$377M
$14M 11.27%
1,264,651
-105,170
-8% -$1.48M
TELA icon
3
TELA Bio
TELA
$32.7M
$7.11M 5.74%
2,353,099
+1,243,099
+112% +$3.5M
LKFT
4
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.97B
$5.5M 4.44%
200,000
-278,659
-58% -$7.77M
ZVRA icon
5
Zevra Therapeutics
ZVRA
$755M
$4.98M 4.02%
597,700
-102,300
-15% -$873K
VSTM icon
6
Verastem
VSTM
$530M
$4.5M 3.63%
870,000
-440,287
-34% -$1.73M
ACAD icon
7
Acadia Pharmaceuticals
ACAD
$4.38B
$4.04M 3.26%
220,000
+23,105
+12% +$373K
OPTN
8
DELISTED
OptiNose
OPTN
$3.93M 3.17%
588,657
+209,418
+55% +$1.84M
ANIK icon
9
Anika Therapeutics
ANIK
$203M
$3.92M 3.17%
238,222
+48,914
+26% +$965K
INDV icon
10
Indivior Pharmaceuticals
INDV
$4.79B
$3.79M 3.06%
305,000
+35,000
+13% +$360K
ESTA icon
11
Establishment Labs
ESTA
$2.72B
$3.69M 2.98%
80,002
+5,002
+7% +$218K
IKT icon
12
Inhibikase Therapeutics
IKT
$331M
$3.68M 2.97%
+1,132,388
New +$2.82M
URGN icon
13
UroGen Pharma
URGN
$1.96B
$3.45M 2.79%
324,324
+43,979
+16% +$527K
XOMA
14
DELISTED
Xoma
XOMA
$3.3M 2.67%
125,700
-69,396
-36% -$2.03M
DAWN
15
DELISTED
Day One Biopharmaceuticals
DAWN
$2.98M 2.4%
235,000
+29,325
+14% +$408K
IRWD icon
16
Ironwood Pharmaceuticals
IRWD
$635M
$2.87M 2.32%
648,785
-351,215
-35% -$1.42M
SCPH
17
DELISTED
scPharmaceuticals
SCPH
$2.42M 1.95%
683,530
-95,344
-12% -$365K
SRZN icon
18
Surrozen
SRZN
$255M
$1.97M 1.59%
137,200
+27,200
+25% +$289K
INO icon
19
Inovio Pharmaceuticals
INO
$92.1M
$1.92M 1.55%
+1,050,000
New +$4.65M
ENTA icon
20
Enanta Pharmaceuticals
ENTA
$400M
$1.91M 1.54%
+331,900
New +$3.18M
MYO icon
21
Myomo
MYO
$36.7M
$1.77M 1.43%
274,426
+174,426
+174% +$849K
CALC icon
22
CalciMedica
CALC
$11.6M
$1.66M 1.34%
+468,793
New +$1.64M
ACRS icon
23
Aclaris Therapeutics
ACRS
$793M
$1.65M 1.33%
663,405
-1,795,468
-73% -$4.47M
PROF
24
Profound Medical
PROF
$249M
$1.5M 1.21%
+200,000
New +$1.54M
JAZZ icon
25
Jazz Pharmaceuticals
JAZZ
$15.5B
$1.23M 0.99%
10,000
-45,000
-82% -$5.3M
1
2 3

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
TGP
TMT General Partner Hong Kong $250M AUM 6.05% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return

Stonepine Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, Stonepine Capital Management held 58 positions worth $124M, down 22% from $158M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Stonepine Capital Management withdrew a net $23.6M in Q4 2024, closing 6 positions and reducing 17 holdings. Its most notable exit was Royalty Pharma, an estimated $6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

Against the trend, Stonepine Capital Management opened a new position in Inovio Pharmaceuticals worth $1.92M.

  • Stonepine Capital Management's largest Q4 2024 buy was Inovio Pharmaceuticals: 1,050,000 shares worth $1.92M.
  • Stonepine Capital Management added most to TELA Bio in Q4 2024, an estimated $3.5M increase.
  • Stonepine Capital Management's biggest Q4 2024 reduction was ADMA Biologics, cutting an estimated $11.8M.
  • Stonepine Capital Management fully exited Royalty Pharma in Q4 2024, selling an estimated $6M.
  • Stonepine Capital Management's ten largest holdings make up 59% of its $124M portfolio in Q4 2024.
  • Stonepine Capital Management opened 20 new positions and closed 6 in Q4 2024.
  • Stonepine Capital Management's portfolio value fell 22% quarter-over-quarter to $124M.

Based on Stonepine Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.